SARS-CoV-2 Nucleocapsid Antibody Cat. No.: 10-065

Availability: In stock

$0.00

 Price Options

$0.00
psi-iconSpecifications
SPECIES REACTIVITY: Virus
IMMUNOGEN: Recombinant nucleoprotein of SARS-CoV (severe acute respiratory syndrome).The nucleocapsid protein is expressed in the internal nucleocapsid of SARS-CoV-2.
TESTED APPLICATIONS: ELISA, IHC, WB
APPLICATIONS: ELISA, IHC, WB (Quality Tested by ProSci); FC (Other applications as reported in literature)
SPECIFICITY: Anti-SARS-CoV-2 Nucleocapsid, clone 1C7C7, specifically targets an epitope on the SARS-CoV-2 and SARS-CoV nucleocapsid protein. This antibody does not cross-react with the nucleocapsid of other common human coronaviruses, OC43 and 229E

psi-iconProperties
PURIFICATION:>95% by SDS Page
CLONALITY:Monoclonal
ISOTYPE:Mouse IgG2a
CONJUGATE:Unconjugated
PHYSICAL STATE:Liquid
BUFFER:This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (PBS) pH 7.2 - 7.4, 150 mM NaCl with no carrier protein, potassium, calcium or preservatives added.
CONCENTRATION:>1.0 mg/ml
STORAGE CONDITIONS:Functional grade preclinical antibodies may be stored sterile as received at 2-8˚ C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80˚ C. Avoid Repeated Freeze Thaw Cycles.

psi-iconAdditional Info
ALTERNATE NAMES:SARS-CoV-2 Nucleocapsid, SARS-CoV-2 Nucleoprotein, Protein N, SARS-CoV N Protein
PROTEIN GI NO.:SARS-CoV-2
USER NOTE:43740575
psi-iconBackground and References
REFERENCES:1) Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19), is an enveloped, single-stranded, positive-sense RNA virus that belongs to the Coronaviridae family 1. The SARS-CoV-2 genome, which shares 79.6% identity with SARS-CoV, encodes four essential structural proteins: the spike (S), envelope (E), membrane (M), and nucleocapsid protein (N) 2. The N protein is 46 kDa and consists of two highly conserved structural domains, the N-terminal domain (NTD) and C-terminal domain (CTD), connected by a linker region. The NTD and CTD are involved in RNA binding and self-oligomerization, respectively 3, 4. The primary function of the N protein is to bind to and package the viral RNA genome into a helical ribonucleoprotein complex 5. The N protein is also involved in other critical steps of the viral life cycle, including transcription, replication, and modulating infected cell signaling pathways 6, 7. The N protein is abundantly expressed during infection and is highly conserved, sharing 90% amino acid homology with the SARS-CoV N protein 8. It is also immunogenic, and antibodies 8,9 and memory T cells 10, 11 targeting the N protein are present in the sera of convalescent COVID-19 patients, identifying the N protein as a suitable candidate for vaccine development and diagnostic assays. Diagnostic assays based on the N protein effectively detect antibodies in the sera of patients infected with SARS-CoV-2 12. The N protein also contributes to immune evasion by antagonizing antiviral RNAi 13, suggesting its potential value as a targeted therapeutic.
2) Zhou, P., Yang, X., Wang, X. et al. Nature 579, 270–273. 2020.
3) Wu, F., Zhao, S., Yu, B. et al. Nature 579, 265–269. 2020.
4) Kang S, Yang M, Hong Z, et al. Acta Pharm Sin B. 10.1016/j.apsb.2020.04.009. 2020.
5) Chang CK, Sue SC, Yu TH, et al. J Biomed Sci. 13(1):59-72. 2006.
6) Hsieh PK, Chang SC, Huang CC, et al. J Virol. 79(22):13848-13855. 2005.
7) Surjit M, Lal SK. Infect Genet Evol. 8(4):397-405. 2008.
8) Hurst KR, Ye R, Goebel SJ, Jayaraman P, Masters PS. J Virol. 84(19):10276-10288. 2010.
9) Guo L., Ren L., Yang S., et al. Clinical Infectious Diseases: an Official Publication of the Infectious Diseases Society of America. 2020.
10) To K.K., Tsang O.T., Leung W.S., et al. Lancet Infect. Dis. 2020.
psi-iconCITATIONS
CITATIONS: 1)Ni L, Ye F, Cheng ML, et al. Immunity. 52(6):971-977.e3. 2020.

ANTIBODIES FOR RESEARCH USE ONLY.

For additional information, visit ProSci's Terms & Conditions Page.